ストックスクリーナーアプリを入手
10.34
1.37%
0.14
前日終値:
$10.20
開ける：
$10.3
24時間の取引高:
320.24K
Relative Volume:
0.66
時価総額：
$234.33M
収益：
$146.07M
当期純損益:
$-196.04M
株価収益率:
-0.6221
EPS:
-16.621
ネットキャッシュフロー:
$-75.37M
1週間 パフォーマンス:
+7.71%
1か月 パフォーマンス:
+13.50%
6か月 パフォーマンス:
+19.12%
1年 パフォーマンス:
+106.80%
1日の値動き範囲:
$9.88
$10.59
1週間の範囲:
$9.20
$10.86
52週間の値動き範囲:
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
10.34 | 234.33M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Rodman & Renshaw | Buy |
| 2026-02-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 再開されました | H.C. Wainwright | Buy |
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm stock trades steadily as investors watch Selinexor franchise - ad-hoc-news.de
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary - Quartr
Karyopharm Therapeutics faces a data setback as investors weigh late-stage cancer pipeline - ad-hoc-news.de
KPTIKaryopharm Therapeutics Inc Latest SEC Filings - Finviz
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm gives 4 new hires stock awards vesting over 3 years - Stock Titan
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Value Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Dynamic Index - marketscreener.com
Price to earnings forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Enterprise value to revenue forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $KPTI - MarketBeat
Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI) - TradingView
25K0 Forecast — Price Target — Prediction for 2027 - TradingView
KPTI Forecast — Price Target — Prediction for 2027 - TradingView
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dyne Therapeutics Appoints Barry Greene to Board of Directors - GlobeNewswire
Karyopharm Therapeutics Inc (KPTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell - Seeking Alpha
Karyopharm Therapeutics Inc (KPTI) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright reiterates Karyopharm stock rating on trial data By Investing.com - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Karyopharm Therapeutics Inc (KPTI) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Karyopharm Therapeutics Inc (KPTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Karyopharm Therapeutics presents new Phase 3 SENTRY trial data in myelofibrosis at EHA - Traders Union
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - TradingView
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - GlobeNewswire Inc.
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update - Traders Union
Cantor Fitzgerald reiterates Overweight on Karyopharm stock - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Karyopharm stock By Investing.com - Investing.com South Africa
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Yahoo Finance
T. Rowe Price (KPTI) files Schedule 13G/A showing 6.6% position - Stock Titan
KPTI: Phase III data in myelofibrosis and endometrial cancer signal major advances and rapid adoption - TradingView
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Cancer expert joins Karyopharm's June 8 investor webcast - Stock Titan
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-06-02 - Seeking Alpha
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):